Edition:
United Kingdom

SSY Group Ltd (2005.HK)

2005.HK on Hong Kong Stock

7.25HKD
7:25am GMT
Change (% chg)

HK$0.19 (+2.69%)
Prev Close
HK$7.06
Open
HK$6.93
Day's High
HK$7.33
Day's Low
HK$6.93
Volume
3,178,000
Avg. Vol
5,372,532
52-wk High
HK$9.46
52-wk Low
HK$5.17

Latest Key Developments (Source: Significant Developments)

SSY Group Posts FY Revenue HK$4,181 Mln, Up 35.9 Pct
Wednesday, 13 Mar 2019 

March 13 (Reuters) - SSY Group Ltd <2005.HK>::FY REVENUE OF HK$4,181 MILLION , REPRESENTING AN INCREASE OF 35.9 PCT.FY NET PROFIT ATTRIBUTABLE HK$911.8 MILLION VERSUS HK$664.7 MILLION.RESOLVED TO PAY A FINAL DIVIDEND OF HK$0.05 PER SHARE.SSY GROUP - PRODUCTION LINE FOR LARGE-VOLUME SOFT BAG INFUSION IS UNDER CONSTRUCTION; EXPECTED TO BE READY FOR PRODUCTION IN MAY 2019.  Full Article

SSY Group Updates On Product Development
Tuesday, 5 Mar 2019 

March 5 (Reuters) - SSY Group Ltd <2005.HK>::GETS APPROVAL FOR DRUG PRODUCTION AND REGISTRATION FOR BALANCED SALT IRRIGATING SOLUTION (1000ML) FROM NATIONAL DRUG ADMINISTRATION OF CHINA.  Full Article

SSY Group Sees Rise Ranging From 33 Pct To 40 Pct In Profit Attributable For FY
Monday, 18 Feb 2019 

Feb 18 (Reuters) - SSY Group Ltd <2005.HK>::SEES INCREASE RANGING FROM 33% TO 40% IN PROFIT ATTRIBUTABLE FOR YEAR.EXPECTED RESULT DUE TO INCREASES IN SALES VOLUME AND AVERAGE SELLING PRICE OF INTRAVENOUS INFUSION SOLUTIONS.  Full Article

SSY Group Gets Approvals For Drug Production And Registration Of Certain Products
Sunday, 6 Jan 2019 

Jan 7 (Reuters) - SSY Group Ltd <2005.HK>::GETS APPROVALS FOR DRUG PRODUCTION, REGISTRATION OF AMBROXOL HYDROCHLORIDE INJECTION & TIROFIBAN HYDROCHLORIDE & SODIUM CHLORIDE INJECTION.  Full Article

SSY Group Posts HY Net Profit Of HK$446 Mln
Monday, 27 Aug 2018 

Aug 27 (Reuters) - SSY Group Ltd <2005.HK>::HY REVENUE HK$2,093 MILLION, UP 57.9%.DECLARED INTERIM DIVIDEND OF HK$0.04 PER SHARE.HY NET PROFIT HK$446 MILLION, UP 54.7%.  Full Article

SSY Group Expects Significant Increase In HY Profit Attributable Ranging From 50% To 60%
Monday, 6 Aug 2018 

Aug 6 (Reuters) - SSY Group Ltd <2005.HK>::EXPECTED TO RECORD A SIGNIFICANT INCREASE IN PROFIT ATTRIBUTABLE RANGING FROM 50% TO 60% FOR HY.INCREASE DUE TO INCREASES IN SALES VOLUMES AND AVERAGE SELLING PRICES OF INTRAVENOUS INFUSION SOLUTIONS.  Full Article

SSY Group Updates On Product Approval
Monday, 4 Jun 2018 

June 4 (Reuters) - SSY Group Ltd <2005.HK>::OBTAINED APPROVALS FOR DRUG PRODUCTION & REGISTRATION FOR POTASSIUM CHLORIDE INJECTION FROM CHINA FOOD AND DRUG ADMINISTRATION.  Full Article

SSY Group Obtained Approvals For Drug Production And Registration From China FDA
Tuesday, 24 Apr 2018 

April 24 (Reuters) - SSY Group Ltd <2005.HK>::OBTAINED APPROVALS FOR DRUG PRODUCTION AND REGISTRATION FOR BALANCED SALT SOLUTION (IRRIGATING) (250ML AND 500ML) FROM CHINA FDA.  Full Article

SSY Group Ltd Posts Qtrly Turnover Of About Hk$1.10 Bln
Monday, 16 Apr 2018 

April 16 (Reuters) - SSY Group Ltd <2005.HK>::QTRLY TURNOVER INCREASED BY 74% AS COMPARED WITH SAME PERIOD OF 2017 TO ABOUT HK$1,099 MILLION.QTRLY UNAUDITED PROFIT ATTRIBUTABLE TO SHAREHOLDERS OF CO HK$242 MILLION, UP 111%.  Full Article

SSY Group Posts FY Net Profit Of HK$665 Mln, Up 35.8 Pct
Tuesday, 27 Mar 2018 

March 27 (Reuters) - Ssy Group Ltd <2005.HK>::BOARD RESOLVED TO PAY A FINAL DIVIDEND OF HK$0.04 PER SHARE FOR YEAR ENDED 31 DECEMBER 2017.FY REVENUE OF HK$3,076 MILLION, UP 30.3 PCT.FY NET PROFIT OF HK$665 MILLION, UP 35.8 PCT.  Full Article